What is Orthocell?
Orthocell is a pioneering biotechnology firm dedicated to developing advanced regenerative medicine products that harness the body's inherent healing capabilities to restore mobility, function, and performance. Their flagship products, such as Remplir, are engineered to bolster the body's repair mechanisms, offering novel therapeutic options for healthcare practitioners managing complex injuries. As an ASX-listed entity, Orthocell is at the forefront of translating cutting-edge Australian biomedical research into viable commercial medical solutions, collaborating with key opinion leaders to advance patient care.
How much funding has Orthocell raised?
Orthocell has raised a total of $8M across 1 funding round:
Stock Offering
$8M
Stock Issuance/Offering (2014): $8M, investors not publicly disclosed
What's next for Orthocell?
The substantial enterprise-level backing Orthocell has received, particularly the recent strategic investment, signals a critical growth phase. This capital infusion is expected to accelerate product development, expand clinical trials, and bolster market penetration for their regenerative therapies. Orthocell's trajectory indicates a strong potential for further innovation and market leadership in the rapidly evolving field of regenerative medicine, positioning them for significant future advancements and commercial success.
See full Orthocell company page
